GPDS1
MCID: GLC098
MIFTS: 44

Glaucoma-Related Pigment Dispersion Syndrome (GPDS1)

Categories: Eye diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Glaucoma-Related Pigment Dispersion Syndrome

MalaCards integrated aliases for Glaucoma-Related Pigment Dispersion Syndrome:

Name: Glaucoma-Related Pigment Dispersion Syndrome 57 12 44
Pigment Dispersion Syndrome 57 12 73 13 15 70
Glaucoma, Pigment-Dispersion Type 57
Pigment Dispersion Syndrome; Pds 57
Pigment-Dispersion Type Glaucoma 12
Pigment-Dispersion Syndrome 20
Glaucoma, Open-Angle 70
Gpds1 57
Pds 57

Characteristics:

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
autosomal dominant

Miscellaneous:
usual onset under age 30 years


HPO:

31
glaucoma-related pigment dispersion syndrome:
Inheritance autosomal dominant inheritance
Onset and clinical course young adult onset


Classifications:



External Ids:

Disease Ontology 12 DOID:0060680
OMIM® 57 600510
MeSH 44 C563184
MedGen 41 C1271398
UMLS 70 C0017612 C1271398

Summaries for Glaucoma-Related Pigment Dispersion Syndrome

GARD : 20 Pigment-dispersion syndrome is an eye disorder that occurs when pigment granules that normally adhere to the back of the iris (the colored part of the eye) flake off into the clear fluid produced by the eye ( aqueous humor ). These pigment granules may flow towards the drainage canals of the eye, slowly clogging them and raising the pressure within the eye (intraocular pressure or IOP). This rise in eye pressure can cause damage to the optic nerve (the nerve in the back of the eye that carries visual images to the brain). If the optic nerve becomes damaged, pigment-dispersion syndrome becomes pigmentary glaucoma. This happens in about 30% of cases. Pigment-dispersion syndrome commonly presents between the second and fourth decades, which is earlier than other types of glaucoma. While men and women are affected in equal numbers, men develop pigmentary glaucoma up to 3 times more often than women. Myopia (nearsightedness) appears to be an important risk factor in the development of pigment-dispersion syndrome and is present in up to 80% of affected individuals. The condition may be sporadic or follow an autosomal dominant pattern of inheritance with reduced penetrance. At least one gene locus on chromosome 7 has been identified. Pigment-dispersion syndrome can be treated with eye drops or other medications. In some cases, laser surgery may be performed.

MalaCards based summary : Glaucoma-Related Pigment Dispersion Syndrome, also known as pigment dispersion syndrome, is related to ocular hypertension and primary angle-closure glaucoma. An important gene associated with Glaucoma-Related Pigment Dispersion Syndrome is GPDS1 (Glaucoma-Related Pigment Dispersion Syndrome 1). The drugs Polymyxin B and Trimethoprim have been mentioned in the context of this disorder. Affiliated tissues include eye, bone marrow and bone, and related phenotypes are optic atrophy and myopia

Disease Ontology : 12 An eye disease characterized by slit-like depigmented areas of the iris with up to 50% of patients going on to develop glaucoma.

Wikipedia : 73 Pigment dispersion syndrome (PDS) is an eye disorder that can lead to a form of glaucoma known as... more...

More information from OMIM: 600510

Related Diseases for Glaucoma-Related Pigment Dispersion Syndrome

Diseases related to Glaucoma-Related Pigment Dispersion Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 146)
# Related Disease Score Top Affiliating Genes
1 ocular hypertension 30.3 WDR36 TMCO1 OPTN MYOC
2 primary angle-closure glaucoma 29.8 OPTN MYOC CYP1B1
3 optic nerve disease 29.8 WDR36 OPTN MYOC
4 corneal edema 29.7 MYOC CYP1B1
5 coloboma of macula 29.0 SIX6 PITX2 FOXC1
6 megalocornea 28.9 WDR36 PITX2 MYOC FOXC1 CYP1B1
7 glaucoma 3, primary congenital, a 28.5 WDR36 PITX2 OPTN MYOC FOXC1 CYP1B1
8 juvenile glaucoma 28.0 WDR36 PITX2 OPTN MYOC LOXL1 FOXC1
9 intraocular pressure quantitative trait locus 27.6 WDR36 TMCO1 PITX2 OPTN MYOC LOXL1
10 open-angle glaucoma 27.3 WDR36 TMCO1 SIX6 OPTN MYOC LOXL1
11 glaucoma, primary open angle 26.8 WDR36 TMCO1 SIX6 PITX2 OPTN MYOC
12 pendred syndrome 11.3
13 pendred syndrome/nonsyndromic enlarged vestibular aqueduct 11.1
14 ehlers-danlos syndrome, spondylodysplastic type, 1 11.1
15 spondylodysplastic ehlers-danlos syndrome 10.9
16 branchiootic syndrome 1 10.5
17 goiter 10.5
18 refractive error 10.5
19 deafness, autosomal recessive 4, with enlarged vestibular aqueduct 10.5
20 rare genetic deafness 10.5
21 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.4
22 sensorineural hearing loss 10.4
23 autosomal recessive non-syndromic sensorineural deafness type dfnb 10.4
24 myopia 10.4
25 autosomal recessive disease 10.4
26 chronic closed-angle glaucoma 10.2 MYOC LOXL1
27 exfoliation syndrome 10.2
28 peripheral retinal degeneration 10.2 WDR36 MYOC
29 post-traumatic stress disorder 10.2
30 albinism, oculocutaneous, type v 10.2 TYRP1 LYST
31 albinism, oculocutaneous, type vii 10.2 TYRP1 LYST
32 hypothyroidism 10.1
33 ifap syndrome 2 10.1
34 horner's syndrome 10.1
35 pattern dystrophy 10.1
36 microphthalmia, isolated 2 10.1 WDR36 MYOC CYP1B1
37 steroid-induced glaucoma 10.1 WDR36 MYOC CYP1B1
38 borderline personality disorder 10.0
39 personality disorder 10.0
40 cataract 10.0
41 glaucoma 1, open angle, a 10.0 OPTN MYOC CYP1B1
42 acute closed-angle glaucoma 10.0 OPTN MYOC CYP1B1
43 horner syndrome, congenital 10.0
44 marfan syndrome 10.0
45 dowling-degos disease 1 10.0
46 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
47 retinoschisis 1, x-linked, juvenile 10.0
48 yemenite deaf-blind hypopigmentation syndrome 10.0
49 keratoconus 10.0
50 lens subluxation 10.0

Graphical network of the top 20 diseases related to Glaucoma-Related Pigment Dispersion Syndrome:



Diseases related to Glaucoma-Related Pigment Dispersion Syndrome

Symptoms & Phenotypes for Glaucoma-Related Pigment Dispersion Syndrome

Human phenotypes related to Glaucoma-Related Pigment Dispersion Syndrome:

31
# Description HPO Frequency HPO Source Accession
1 optic atrophy 31 HP:0000648
2 myopia 31 HP:0000545
3 open angle glaucoma 31 HP:0012108

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Head And Neck Eyes:
myopia
pigment-dispersion type open-angle glaucoma
optic-nerve degeneration
pigment granule deposition from iris epithelium to other ocular structures
permanent loss of sight

Clinical features from OMIM®:

600510 (Updated 05-Apr-2021)

MGI Mouse Phenotypes related to Glaucoma-Related Pigment Dispersion Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.81 FOXC1 GPNMB LMX1B LOXL1 LYST PITX2
2 craniofacial MP:0005382 9.73 FOXC1 LMX1B LYST PITX2 TMCO1 TYRP1
3 vision/eye MP:0005391 9.36 CYP1B1 FOXC1 GPNMB LMX1B LOXL1 LYST
4 pigmentation MP:0001186 9.35 FOXC1 GPNMB LYST PITX2 TYRP1

Drugs & Therapeutics for Glaucoma-Related Pigment Dispersion Syndrome

Drugs for Glaucoma-Related Pigment Dispersion Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 199)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Polymyxin B Approved, Vet_approved Phase 4 1404-26-8
2
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
3
Dorzolamide Approved Phase 4 120279-96-1 3154 5284549
4
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
5
Brinzolamide Approved Phase 4 138890-62-7 68844
6
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
7
Loteprednol Approved, Experimental Phase 4 82034-46-6, 129260-79-3 9865442 444025
8
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
9
Apraclonidine Approved Phase 4 66711-21-5 2216
10
Sorbitol Approved Phase 4 50-70-4 5780
11
Fluorouracil Approved Phase 4 51-21-8 3385
12
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
13
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
14
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
15
tannic acid Approved Phase 4 1401-55-4
16
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
17
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
18
Bevacizumab Approved, Investigational Phase 4 216974-75-3
19
Lutein Approved, Investigational, Nutraceutical Phase 4 127-40-2 5281243
20
Maleic acid Experimental Phase 4 110-16-7 444266
21 Gastrointestinal Agents Phase 4
22 Antineoplastic Agents, Hormonal Phase 4
23 Hormones Phase 4
24 glucocorticoids Phase 4
25 Hormone Antagonists Phase 4
26 Polymyxins Phase 4
27 Carbonic Anhydrase Inhibitors Phase 4
28 Mitomycins Phase 4
29 Antibiotics, Antitubercular Phase 4
30 Alkylating Agents Phase 4
31 Anti-Bacterial Agents Phase 4
32 Anti-Allergic Agents Phase 4
33 Anti-Inflammatory Agents Phase 4
34 Anti-Asthmatic Agents Phase 4
35 Respiratory System Agents Phase 4
36 Dermatologic Agents Phase 4
37 Bronchodilator Agents Phase 4
38 Anti-Infective Agents, Local Phase 4
39 Benzalkonium Compounds Phase 4
40 Antiemetics Phase 4
41 Immunosuppressive Agents Phase 4
42 Antimetabolites Phase 4
43 Carotenoids Phase 4
44 Anesthetics Phase 4
45 cefuroxime axetil Phase 4
46 Lubricant Eye Drops Phase 4
47 Adrenergic alpha-Agonists Phase 4
48 Pharmaceutical Solutions Phase 4
49 Ophthalmic Solutions Phase 4
50 Adrenergic Agonists Phase 4

Interventional clinical trials:

(show top 50) (show all 699)
# Name Status NCT ID Phase Drugs
1 A Prospective Evaluation of Mild to Moderate Open-Angle Glaucoma Subjects With Cataract Treated With Cataract Surgery Plus One Trabecular Micro-bypass Stent and One Suprachoroidal Stent Unknown status NCT03255785 Phase 4
2 A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With One Suprachoroidal Stent Unknown status NCT01252914 Phase 4
3 A Study of the Glaukos Trabecular Micro-bypass Stent in Open Angle Glaucoma Subjects 1 Stent Versus 2 Stents Unknown status NCT00326079 Phase 4
4 A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost Ophthalmic Solution 0.004% Unknown status NCT01444040 Phase 4 Travoprost
5 A Prospective Evaluation of Open-angle Glaucoma Subjects on One Topical Hypotensive Medication (Prostaglandin) Treated With Two Trabecular Micro-bypass Stents (iStent Inject) Unknown status NCT02868190 Phase 4
6 An 8 Week Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Open Angle Glaucoma Unknown status NCT02792803 Phase 4 Xalatan;Apo-Latanoprost;Co-Latanoprost
7 Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients Unknown status NCT02053298 Phase 4 Timolol & Dorzolamide
8 Phase 4 Study to Evaluate Efficacy And Safety of Three Different Preparations of Latanoprost 0,005% Eyedrops in Subjects Affected by Primary Open Angle Glaucoma Unknown status NCT01580254 Phase 4 IOPIZE© Latanoprost eyedrops;GALAXIA© Latanoprost eyedrops;Latanoprost RATIOPHARM© latanoprost eyedrops
9 Semi-Automated Patterned Laser Trabeculoplasty Unknown status NCT00804323 Phase 4
10 A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medications (One a Prostaglandin) Treated With Two Trabecular Micro-bypass Stents (iStent Inject) and a Postoperative Topical Prostaglandin Unknown status NCT02873806 Phase 4 Topical travoprost;Tobramycin;Dexamethasone
11 Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated Completed NCT01243567 Phase 4 bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution;latanoprost 0.005% ophthalmic solution
12 Choroidal Thickness and Its Correlations With Ocular Parameters in Cases With Primary Open-angle Glaucoma Completed NCT03966560 Phase 4 Brimonidine Tartrate;Dorzolamide (as Dorzolamide Hydrochloride) 20 Mg/mL and Timolol (as Timolol Maleate) 5 Mg/mL Eye Drops;Brinzolamide/Timolol 10 MG/1 ML-5 MG/1 ML Ophthalmic Suspension;Travoprost and Timolol;Bimatoprost and Timolol;Latanoprost
13 The Impact of Topical Prostaglandin Analogs on the Biomechanical Properties of the Cornea in Patients With Open Angle Glaucoma Completed NCT02388360 Phase 4 topical prostaglandin analogs
14 Effect of Nailfold Application of Latanoprostene Bunod on Nailfold Capillary Blood Flow Completed NCT03949244 Phase 4 Latanoprost 0.005%;Latanoprost bunod 0.024%;Normal saline 0.9%
15 A Multicenter, Open-label Study of Rhopressa® (Netarsudil Ophthalmic Solution) 0.02% for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting Completed NCT03808688 Phase 4 Netarsudil Ophthalmic Solution 0.02%
16 A 12-Week Randomized, Evaluator-Masked, Parallel-Group, Multinational, Multi-Center Study Comparing The Efficacy And Safety Of The Fixed Combination Of Latanoprost And Timolol (Xalacom) With The Fixed Combination Of Dorzolamide And Timolol (Cosopt) In Patients With Open-Angle Glaucoma Or Ocular Hypertension. Completed NCT00140049 Phase 4 Xalacom;Cosopt
17 A 3-month Study Investigating the 24-hour Efficacy With the Preservative-free Tafluprost/Timolol Fixed Combination Dosed Morning, or Evening in Subjects With Open-angle Glaucoma Insufficiently Controlled With Latanoprost Monotherapy Completed NCT03612817 Phase 4 Tafluprost/timolol fixed combination
18 Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed NCT01253902 Phase 4 bimatoprost ophthalmic solution 0.01%;travoprost ophthalmic solution 0.004%;latanoprost ophthalmic solution 0.005%
19 A 12-Month, Phase 4, Open Label, Multicenter, Trial to Assess the Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG) Completed NCT02863705 Phase 4 brimonidine tartrate/timolol malate Ophthalmic Solution;bimatoprost ophthalmic solution 0.01%
20 A Randomized Clinical Trial Comparing the Intraocular Pressure Changes With the Use of Loteprednol and Dexamethasone After Pterygium Surgery Completed NCT00781300 Phase 4 Loteprednol Etabonate 0.5%;Dexamethasone 0.1%
21 Open Multicenter Study on the Efficacy of Xalatan at 3 Months as First-line Therapy in Naive Patients With Ocular Hypertension (OH) or Open Angle Glaucoma (OAG), Based on Initial Intraocular Pressure (IOP): 20 mmHg Less Than or Equal to IOP Less Than 24 mmHg, IOP Greater Than or Equal to 24 mmHg Completed NCT00647101 Phase 4 Latanoprost
22 An Open, Non-randomized Study on the Effect of Changing From Preserved Prostaglandin Formulations to Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma on Tear Film Thickness Completed NCT03204487 Phase 4 Tafluprost 15µg/ml
23 Evaluation of the Safety of GANFORT® (Bimatoprost 0.03% Plus Timolol 0.5%) Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension Completed NCT02571712 Phase 4 bimatoprost 0.03% plus timolol 0.5%
24 A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02020512 Phase 4 0.03% Bimatoprost
25 Patient Satisfaction With Timolol Maleate in Sorbate, Generic Timolol Gel Forming Solution or Timolol Hemihydrate in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00804648 Phase 4 Timolol Maleate in Sorbate;Timolol hemihydrate;Timolol maleate gel forming solution
26 A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) Completed NCT01594970 Phase 4 Bimatoprost 0.01%
27 A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02003534 Phase 4 0.15% Brimonidine Tartrate
28 Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction Completed NCT01547598 Phase 4 travoprost ophthalmic solution 0.004%;travoprost 0.004% / timolol 0.5% combination ophthalmic solution;Bimatoprost ophthalmic solution 0.01%
29 A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02061683 Phase 4 Bimatoprost 0.03%
30 24-hour IOP-lowering Effect of Brimonidine 0.1% Completed NCT00457795 Phase 4 brimonidine 0.1% (Alphagan® P)
31 Latanoprost Versus Fotil Completed NCT00304785 Phase 4 latanoprost 0.005%;Fotil;placebo
32 Lumigan Versus Cosopt Completed NCT00273455 Phase 4 bimatoprost 0.03%;dorzolamide 2%/timolol maleate 0.5% fixed combination;placebo
33 Assessment of Late Day IOP Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®) Completed NCT01464424 Phase 4 Travoprost 0.004% ophthalmic solution;Bimatoprost 0.01% ophthalmic solution
34 A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent) or Travoprost Ophthalmic Solution 0.004% Completed NCT01443988 Phase 4 Travoprost
35 Comparative Evaluation of Intraocular Pressure During the 24 Hour in Patients Affected by Primary Open-angle Glaucoma and Ocular Hypertension: Latanoprost 0.005% Versus Tafluprost 0.0015% Ophthalmic Solutions Completed NCT01162603 Phase 4 TAFLUPROST 0.0015% EYEDROPS;LATANOPROST 0.005% EYEDROPS
36 Multi-Center Study Assessing the Efficacy and Tolerability of TRAVATAN® Solution Without BAK, Containing Polyquad® Preservative (0.004% Travoprost) in Patients Previously on Latanoprost 0.005% or Bimatoprost 0.01% Ophthalmic Solution Monotherapy Completed NCT01493427 Phase 4 Travoprost 0.004%
37 24-hour IOP With DTFC and LTFC Monotherapies and the Adjunctive Therapy of DTFC and Latanoprost in Open-angle Glaucoma Insufficiently Controlled With Latanoprost Monotherapy. Completed NCT00397241 Phase 4 Drug: dorzolamide/timolol;Drug: latanoprost/timolol;dorzolamide/timolol and latanoprost;placebo (artificial tears)
38 24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients Completed NCT00330577 Phase 4 timolol maleate 0.5%;latanoprost/timolol fixed combination;placebo (artificial tears)
39 A Multiple-Dose Study of the IOP-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% When Added to a PGA as Adjunctive Therapy Over a 24 Hour Period in Patients With Glaucoma or Ocular Hypertension Completed NCT00300079 Phase 4 brinzolamide 1.0%
40 Assessing Cosopt Switch Patients Completed NCT00273442 Phase 4 timolol maleate;dorzolamide/timolol maleate fixed combination
41 Cosopt Versus Xalatan Completed NCT00273429 Phase 4 timolol maleate 0.5%;dorzolamide/timolol maleate fixed combination;latanoprost 0.005%;placebo
42 Ocular Surface Conditions in Asian Glaucoma Patients With Existing Corneal Disorders Switching From Preserved Prostaglandin Analogues Monotherapy to Preservative-free Tafluprost Completed NCT04654611 Phase 4 preservative free tafluprost 0.0015%
43 A Prospective Evaluation of Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Treated With Two Trabecular Micro-bypass Stents Completed NCT01252862 Phase 4
44 The Effect of Inhaled Corticosteroids on Intraocular Pressure in Patients With Ocular Hypertension or Controlled Glaucoma. Completed NCT02338362 Phase 4 Fluticasone propionate inhaler;Saline placebo inhaler
45 Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients Completed NCT03104621 Phase 4 Benzalkonium chloride (BAK);0.0015% tafluprost
46 A Study of the Glaukos Trabecular Micro-Bypass Stent in Refractory Open Angle Glaucoma Subjects. Completed NCT00326040 Phase 4
47 A Study of the Glaukos Trabecular Micro-Bypass Stent in Combination With Cataract Surgery in Open Angle Glaucoma Subjects. Completed NCT00326014 Phase 4
48 Influence of Travoprost 0.004% and Latanoprost 0.005% on Retinal Vascular Diameter and Choroidal Blood Flow in Glaucoma Patients Completed NCT00308945 Phase 4 travoprost 0.004% (drug);latanoprost 0.005% (drug)
49 A Randomized Post-Marketing Efficacy And Safety Study Of Xalatan Compared With "Usual Care" Over 36 Months In Patients With Primary Open-Angle Glaucoma, Exfoliative Glaucoma Or Ocular Hypertension Completed NCT00140062 Phase 4 latanoprost 0.005% (Xalatan)
50 Adherence of Patients Using Travalert® for Instillation of a Fixed Combination of Travoprost 0.004%/Timolol 0.5% Compared to a Concomitant Regimen of Travoprost 0.004% and Timolol 0.5% Completed NCT00508469 Phase 4 Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav);Travoprost 0.004% eye drops;Timolol 0.05% eye drops

Search NIH Clinical Center for Glaucoma-Related Pigment Dispersion Syndrome

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Betaxolol
Betaxolol Hydrochloride
bimatoprost
brimonidine
Brimonidine tartrate
brinzolamide
Carteolol
Carteolol Hydrochloride
Dipivefrin
Dipivefrin hydrochloride
dorzolamide
Dorzolamide hydrochloride
Echothiophate Iodide
Epinephrine
epinephrine bitartrate
epinephrine hydrochloride
epinephryl borate
isopropyl unoprostone
latanoprost
Levobunolol
Levobunolol Hydrochloride
Methazolamide
Metipranolol
Metipranolol hydrochloride
Phenylephrine
Phenylephrine bitartrate
Phenylephrine Hydrochloride
Phenylephrine Tannate
Racepinephrine Hydrochloride
Timolol
Timolol Hemihydrate
Timolol Maleate
travoprost
UNOPROSTONE

Cochrane evidence based reviews: glaucoma-related pigment dispersion syndrome

Genetic Tests for Glaucoma-Related Pigment Dispersion Syndrome

Anatomical Context for Glaucoma-Related Pigment Dispersion Syndrome

MalaCards organs/tissues related to Glaucoma-Related Pigment Dispersion Syndrome:

40
Eye, Bone Marrow, Bone, Retina, Endothelial, Skin

Publications for Glaucoma-Related Pigment Dispersion Syndrome

Articles related to Glaucoma-Related Pigment Dispersion Syndrome:

(show top 50) (show all 242)
# Title Authors PMID Year
1
Phenotypic variability of pigment dispersion syndrome in children. 61 57
17210864 2007
2
Atypical pigment dispersion syndrome in a child. 57 61
15059719 2004
3
Age-dependent iris abnormalities in collagen XVIII/endostatin deficient mice with similarities to human pigment dispersion syndrome. 57 61
12766032 2003
4
What is the risk of developing pigmentary glaucoma from pigment dispersion syndrome? 61 57
12788118 2003
5
Interacting loci cause severe iris atrophy and glaucoma in DBA/2J mice. 57 61
10192392 1999
6
A gene responsible for the pigment dispersion syndrome maps to chromosome 7q35-q36. 57 61
9076212 1997
7
Clinical features of five pedigrees genetically linked to the juvenile glaucoma locus on chromosome 1q21-q31. 57 61
9098278 1995
8
Exclusion of chromosome 1q21-q31 from linkage to three pedigrees affected by the pigment-dispersion syndrome. 61 57
7726183 1995
9
Pigment dispersion syndrome: a clinical study. 61 57
7236571 1981
10
Genetic dissection of the Gpnmb network in the eye. 57
21398278 2011
11
Apoptotic retinal ganglion cell death in the DBA/2 mouse model of glaucoma. 57
17074320 2007
12
An iris coloboma preventing pigmentary glaucoma. 57
12860819 2003
13
Mutations in genes encoding melanosomal proteins cause pigmentary glaucoma in DBA/2J mice. 57
11743578 2002
14
Essential iris atrophy, pigment dispersion, and glaucoma in DBA/2J mice. 57
9579474 1998
15
Pigmentary dispersion syndrome and pigmentary glaucoma. A prospective study of the natural history. 57
3947295 1986
16
Inheritance and the pigmentary dispersion syndrome. 57
6571433 1983
17
Pigmentary glaucoma. A 25-year review. 57
5920432 1966
18
Effects of Nd-YAG Laser iridotomy on anterior segment measurements in pigment dispersion syndrome and ocular hypertension. 61
33384165 2021
19
Pigment dispersion syndrome and its implications for glaucoma. 61
33444629 2021
20
Pigment dispersion syndrome diagnosed after photorefractive keratectomy-A case report. 61
33229699 2020
21
A case of dense pigment deposition of the posterior lens capsule. 61
33213412 2020
22
[Bilateral explantation of iris implants due to pigment dispersion syndrome (PDS) and corneal decompensation after cosmetic iris implantation (BrightOcular)]. 61
32025791 2020
23
[Unusual anisocoria]. 61
32588124 2020
24
Reversal of Iris Backbowing in Pigment Dispersion Syndrome. 61
32672616 2020
25
An Iconic Case of Pigmentary Glaucoma: Brief Review of the Literature. 61
32884553 2020
26
Solitary Free-Floating Iris Cyst Associated With Bilateral Pigment Dispersion Syndrome: Report of a Case. 61
31972594 2020
27
Early presentation of pigment dispersion syndrome. 61
31712049 2020
28
Pigment Dispersion Syndrome and Pigmentary Glaucoma in an Emmetropic Young Male. 61
32799252 2020
29
A case of bilateral acute depigmentation of the Iris in one of two identical twins. 61
31906906 2020
30
Near-infrared transillumination imaging combined with aperture photometry for the quantification of melanin in the iris pigment epithelium. 61
32143214 2020
31
Pigment dispersion syndrome presenting as endothelial dystrophy: An atypical presentation. 61
31844799 2019
32
Iris Transillumination Defects in Pigment Dispersion Syndrome. 61
31722155 2019
33
Traumatic Pigment Dispersion Syndrome. 61
32672577 2019
34
Pigment dispersion syndrome and response to laser peripheral iridotomies in a child with Marfan syndrome. 61
31513900 2019
35
Berger's space. 61
31378388 2019
36
High-Resolution, Adaptive Optics Imaging of the Human Trabecular Meshwork In Vivo. 61
31588370 2019
37
Pigment dispersion syndrome and pigmentary glaucoma: a review and update. 61
29721842 2019
38
Correction to: Pigment dispersion syndrome and pigmentary glaucoma: a review and update. 61
31172344 2019
39
The Heritability of Pigment Dispersion Syndrome and Pigmentary Glaucoma. 61
30796891 2019
40
Prevalence of Pigment Dispersion Syndrome in Patients Seeking Refractive Surgery. 61
30652983 2019
41
Pseudouveitis and Iris Atrophy in Pigment Dispersion Syndrome after Sulcus Implantation of a One-Piece IOL with Square Edge Haptics (SN6AT6). 61
30763955 2019
42
Non-Synonymous variants in premelanosome protein (PMEL) cause ocular pigment dispersion and pigmentary glaucoma. 61
30561643 2019
43
Scheie's line as a first sign of pigment dispersion syndrome. 61
30527354 2019
44
Pigment Dispersion Syndrome. 61
32672610 2019
45
Case Report: Sequelae of Bilateral Iris Pigment Epithelial Cysts Masquerading as Primary Pigmentary Glaucoma. 61
30570597 2019
46
Combined central retinal vein and cilioretinal artery occlusion related to acute intra-ocular pressure rise of previously unknown pigment dispersion syndrome. 61
29673629 2018
47
Pigment Dispersion Syndrome Mimicking Congenital Horner Syndrome. 61
29329469 2018
48
Molecular Genetics of Pigment Dispersion Syndrome and Pigmentary Glaucoma: New Insights into Mechanisms. 61
29780638 2018
49
[Role of laser peripheral iridotomy in pigmentary glaucoma and pigment dispersion syndrome: A review of the literature [French version]]. 61
29050926 2017
50
Role of laser peripheral iridotomy in pigmentary glaucoma and pigment dispersion syndrome: A review of the literature. 61
28987446 2017

Variations for Glaucoma-Related Pigment Dispersion Syndrome

Expression for Glaucoma-Related Pigment Dispersion Syndrome

Search GEO for disease gene expression data for Glaucoma-Related Pigment Dispersion Syndrome.

Pathways for Glaucoma-Related Pigment Dispersion Syndrome

GO Terms for Glaucoma-Related Pigment Dispersion Syndrome

Cellular components related to Glaucoma-Related Pigment Dispersion Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 melanosome membrane GO:0033162 8.62 TYRP1 GPNMB

Biological processes related to Glaucoma-Related Pigment Dispersion Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 visual perception GO:0007601 9.43 WDR36 SIX6 CYP1B1
2 pigmentation GO:0043473 9.16 TYRP1 LYST
3 melanosome organization GO:0032438 8.96 TYRP1 LYST
4 collagen fibril organization GO:0030199 8.8 LOXL1 FOXC1 CYP1B1

Sources for Glaucoma-Related Pigment Dispersion Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....